ストックスクリーナーアプリを入手
150.00
0.98%
-1.485
アフターアワーズ：
149.29
-0.71
-0.47%
Belite Bio Inc Adr (BLTE) 最新ニュース
Belite Bio (NASDAQ:BLTE) Stock Price Down 5.9%Should You Sell? - MarketBeat
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Rating Increased to Outperform at Mizuho - MarketBeat
FY2025 EPS Estimates for Belite Bio Lowered by HC Wainwright - MarketBeat
Belite Bio (NASDAQ:BLTE) Raised to “Outperform” at Mizuho - Defense World
Belite Bio (NASDAQ:BLTE) Shares Gap UpWhat's Next? - MarketBeat
Belite Bio stock price target raised to $187 from $132 at Benchmark By Investing.com - Investing.com South Africa
Belite Bio stock price target raised to $187 from $132 at Benchmark - Investing.com Nigeria
Is Belite Bio’s Surge Justified by DCF Upside and Price to Book Signals? - Sahm
Belite Bio prices 2.27M ADSs at $154.00 to raise $350M in public offering - MSN
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of “Hold” by Brokerages - Defense World
Belite Bio Reports Increased Cash Reserves Amid Rising R&D Costs - The Globe and Mail
Belite Bio Prices $350 Million ADS Offering to Boost Drug Development - TipRanks
Does Belite Bio Inc ADR (BLTE) offer a good opportunity for investors? - Setenews
Mizuho upgrades Belite Bio stock to Outperform on positive trial data By Investing.com - Investing.com South Africa
Belite Bio (NASDAQ:BLTE) Reaches New 52-Week HighWhat's Next? - MarketBeat
Mizuho upgrades Belite Bio stock to Outperform on positive trial data - Investing.com Australia
Why Belite Bio’s Stock is Making Waves - TipRanks
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Belite Bio prices public offering of ADSs at $154 each - Investing.com
Belite Bio (NASDAQ: BLTE) prices $350M ADS offer to back commercialization, pipeline - Stock Titan
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares - GlobeNewswire Inc.
A Look at Belite Bio (BLTE) Valuation Following Positive Tinlarebant Phase 3 Trial Results - Sahm
Why Belite Bio Stock Soared on Monday - Finviz
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares - markets.businessinsider.com
Belite Bio launches public offering of American Depositary Shares - Investing.com
Belite Bio Announces Public Offering of ADSs to Fund Expansion - TipRanks
Belite Bio stock falls after announcing public offering of ADSs By Investing.com - Investing.com South Africa
Belite Bio stock falls after announcing public offering of ADSs - Investing.com
Belite Bio (NASDAQ: BLTE) begins ADS sale to support pipeline and commercialization - Stock Titan
Belite Bio Shares Surge After Landmark Phase 3 Success in Stargardt Disease - MSN
Belite Bio stock hits all-time high at 154.0 USD By Investing.com - Investing.com Nigeria
Belite Bio stock hits all-time high at 154.0 USD - Investing.com
Belite continues ascent as Stargardt drug hits mark in late-stage trial - BioPharma Dive
Belite Bio stock soars after breakthrough Phase 3 results for Stargardt disease By Investing.com - Investing.com Canada
Belite Bio stock soars after breakthrough Phase 3 results for Stargardt disease - Investing.com Australia
Belite Bio’s tinlarebant shows 36% reduction in Stargardt disease lesions By Investing.com - Investing.com Australia
Belite Bio Shares Dip Despite Promising Trial Results - TipRanks
Belite Bio Reports Breakthrough Phase 3 Results for Stargardt Disease Treatment - TipRanks
Belite Bio's Tinlarebant Achieves Significant Efficacy in Phase 3 Trial for Stargardt Disease - Quiver Quantitative
Belite Bio’s tinlarebant shows 36% reduction in Stargardt disease lesions - Investing.com
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease - Barchart.com
Why Belite Bio’s Stock is on the Rise - TipRanks
Leerink Partnrs Lowers Earnings Estimates for Belite Bio - MarketBeat
Belite Bio FY2025 EPS Estimate Decreased by Leerink Partnrs - Defense World
Cantor Fitzgerald Estimates Belite Bio FY2025 Earnings - Defense World
(BLTE) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
The time has not yet come to remove your chips from the table: Optimum Communications Inc (OPTU) - Setenews
Belite Bio (NASDAQ:BLTE) Now Covered by Cantor Fitzgerald - Defense World
Belite Bio (NASDAQ:BLTE) Shares Up 13.1%Here's Why - MarketBeat
Alibaba, Oscar Health, Ondas Holdings, Lumentum, Tesla And Other Big Stocks Moving Higher On Monday - Benzinga
Tesla, Micron among market cap stock movers on Monday By Investing.com - Investing.com South Africa
1.44%
0.91%
大文字化:
|
ボリューム (24 時間):